Search Results - "VALENSI, PAUL"

Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications by Valensi, Paul

“…The incidence and prevalence of hypertension is increasing worldwide, with approximately 1.13 billion of people currently affected by the disease, often in…”
Get full text

Evidence of a bi-directional relationship between heart failure and diabetes: a strategy for the detection of glucose abnormalities and diabetes prevention in patients with heart failure by Valensi, Paul

“…Prevalence of heart failure (HF) and diabetes are markedly increasing globally. In a population of HF patients, approximately 40% have diabetes which is…”
Get full text

Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes by Thai, Pham Viet, Tien, Hoang Anh, Van Minh, Huynh, Valensi, Paul

“…Triglyceride Glucose (TyG) index has been associated with an increased risk in cardiovascular events. Silent coronary disease is common in patients with type 2…”
Get full text

Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management by Spallone, Vincenza, Ziegler, Dan, Freeman, Roy, Bernardi, Luciano, Frontoni, Simona, Pop-Busui, Rodica, Stevens, Martin, Kempler, Peter, Hilsted, Jannik, Tesfaye, Solomon, Low, Phillip, Valensi, Paul

“…The Cardiovascular Autonomic Neuropathy (CAN) Subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy worked to update CAN guidelines, with regard…”
Get full text

Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments by Tesfaye, Solomon, Boulton, Andrew J.M, Dyck, Peter J, Freeman, Roy, Horowitz, Michael, Kempler, Peter, Lauria, Giuseppe, Malik, Rayaz A, Spallone, Vincenza, Vinik, Aaron, Bernardi, Luciano, Valensi, Paul

“…Preceding the joint meeting of the 19th annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (NEURODIAB) and the 8th…”
Get full text

Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes by Hermans, Michel P, Valensi, Paul

“…The aim of this review is to describe in diabetic patients the determinants underlying atherogenic dyslipidemia, a complex dyslipidemia defined as the…”
Get full text

Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature by Valensi, Paul, Lorgis, Luc, Cottin, Yves

“…Summary The prevalence, incidence, risk factors and prognosis of silent myocardial infarction are less well known than those of silent myocardial ischaemia…”
Get full text

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management by Ceriello, Antonio, Catrinoiu, Doina, Chandramouli, Chanchal, Cosentino, Francesco, Dombrowsky, Annique Cornelia, Itzhak, Baruch, Lalic, Nebojsa Malić, Prattichizzo, Francesco, Schnell, Oliver, Seferović, Petar M., Valensi, Paul, Standl, Eberhard

“…Abstract Type 2 diabetes is one of the most relevant risk factors for heart failure, the prevalence of which is increasing worldwide. The aim of the review is…”
Get full text

Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension by Son, Tran Kim, Toan, Ngo Hoang, Thang, Nguyen, Le Trong Tuong, Huynh, Tien, Hoang Anh, Thuy, Nguyen Hai, Van Minh, Huynh, Valensi, Paul

“…The relationships between glucose abnormalities, insulin resistance (IR) and heart failure (HF) are unclear, especially regarding to the HF type, i.e., HF with…”
Get full text

Performance of the 2019 ESC/EASD guideline strategy for the screening of silent coronary artery disease in patients with diabetes by Valensi, Paul, Berkane, Narimane, Pinto, Sara, Sellier, Nicolas, Soussan, Michael, Nguyen, Minh Tuan, Cosson, Emmanuel

“…The 2019 guidelines for cardiovascular risk stratification by the European Society of Cardiology and European Association for the Study of Diabetes (ESC-EASD)…”
Get full text

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group by Schnell, Oliver, Standl, Eberhard, Catrinoiu, Doina, Itzhak, Baruch, Lalic, Nebojsa, Rahelic, Dario, Skrha, Jan, Valensi, Paul, Ceriello, Antonio

“…The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25-26 October 2018…”
Get full text

Issues for the management of people with diabetes and COVID-19 in ICU by Ceriello, Antonio, Standl, Eberhard, Catrinoiu, Doina, Itzhak, Baruch, Lalic, Nebojsa M, Rahelic, Dario, Schnell, Oliver, Škrha, Jan, Valensi, Paul

“…In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive…”
Get full text

Effects of single and multiple sessions of lower body diastole-synchronized compressions using a pulsating pneumatic suit on endothelium function and metabolic parameters in patients with type 2 diabetes: two controlled cross-over studies by Valensi, Paul, Barber-Chamoux, Nicolas, Rezki, Amel, Lambert, Céline, Pereira, Bruno, Dualé, Christian, Delmas, Dominique, Duclos, Martine

“…Endothelium function is often impaired in patients with type 2 diabetes. We hypothesized that by improving endothelial function using diastole-synchronized…”
Get full text

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group by Schnell, Oliver, Standl, Eberhard, Catrinoiu, Doina, Genovese, Stefano, Lalic, Nebojsa, Lalic, Katarina, Skrha, Jan, Valensi, Paul, Ceriello, Antonio

“…The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26-27 October 2017 in Munich. As in 2015…”
Get full text

Epicardial adipose tissue volume and myocardial ischemia in asymptomatic people living with diabetes: a cross-sectional study by Cosson, Emmanuel, Nguyen, Minh Tuan, Rezgani, Imen, Berkane, Narimane, Pinto, Sara, Bihan, Hélène, Tatulashvili, Sopio, Taher, Malak, Sal, Meriem, Soussan, Michael, Brillet, Pierre-Yves, Valensi, Paul

“…Epicardial adipose tissue (EAT) is considered a novel diagnostic marker for cardiometabolic disease. This study aimed to evaluate whether EAT volume was…”
Get full text

Importance of Observational Studies in Clinical Practice by Ligthelm, Robert J., MD, Borzì, Vito, PhD, Gumprecht, Janusz, MD, PhD, Kawamori, Ryuzo, MD, Wenying, Yang, MD, Valensi, Paul, MD

“…Abstract Background: In this era of evidence-based medicine, clinicians require a comprehensive range of well-designed studies to support prescribing decisions…”
Get full text

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes by Schnell, Oliver, Valensi, Paul, Standl, Eberhard, Ceriello, Antonio

“…Diabetes mellitus (DM) is a major chronic disease with ever‐increasing prevalence and a variety of serious complications for persons with DM, such as…”
Get full text

Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines by Gourdy, Pierre, Schiele, François, Halimi, Jean-Michel, Kownator, Serge, Hadjadj, Samy, Valensi, Paul

“…Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM)…”
Get full text

Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients by Cosson, Emmanuel, Nguyen, Minh Tuan, Chanu, Bernard, Banu, Isabela, Chiheb, Sabrina, Balta, Cristina, Takbou, Karim, Valensi, Paul

“…OBJECTIVE: To evaluate if silent myocardial ischemia (SMI) and silent coronary artery disease (CAD) provide significant additional value to routine…”
Get full text

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes by Valensi, Paul

“…The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the premix,…”
Get full text